Close

Rexahn Pharmaceuticals (RNN) Updates on Supinoxin Phase I; Completes Enrollment in Fourth Dose Group

July 18, 2014 9:01 AM EDT Send to a Friend
Rexahn Pharmaceuticals (AMEX: RNN) announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login